{"disease":{"id":"leukemia-myeloid-acute","name":"leukemia myeloid acute"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06956755","title":"Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia","phase":"","overall_status":"RECRUITING","enrollment_count":6990,"lead_sponsor_name":"Groupe Francophone des Myelodysplasies","has_results":false},{"nct_id":"NCT00898079","title":"Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":2545,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT01688011","title":"Connect® Myeloid Disease Registry","phase":"","overall_status":"TERMINATED","enrollment_count":2013,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT05564390","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01005277","title":"Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","phase":"","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT04687098","title":"Risk-adapted Therapy for Primary Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1034,"lead_sponsor_name":"Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias","has_results":false},{"nct_id":"NCT07205523","title":"High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Yigeng Cao,MD,PhD","has_results":false},{"nct_id":"NCT04726241","title":"The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":960,"lead_sponsor_name":"PedAL BCU, LLC","has_results":false},{"nct_id":"NCT02348489","title":"SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":815,"lead_sponsor_name":"Astex Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03416179","title":"A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":730,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02085408","title":"Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":727,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":true},{"nct_id":"NCT01721876","title":"Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":666,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04988555","title":"A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":606,"lead_sponsor_name":"Sumitomo Pharma America, Inc.","has_results":false},{"nct_id":"NCT06852222","title":"A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT00416598","title":"Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":546,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02847130","title":"Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology","phase":"","overall_status":"COMPLETED","enrollment_count":530,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT01307579","title":"Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":517,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT02115295","title":"Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":508,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01757535","title":"Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":472,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT03268954","title":"Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":454,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT02545283","title":"A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":447,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT05457556","title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":435,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT04811560","title":"A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":420,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT04090268","title":"Precision Exercise in Children With Malignant Hemopathies","phase":"NA","overall_status":"UNKNOWN","enrollment_count":380,"lead_sponsor_name":"University of Milano Bicocca","has_results":false},{"nct_id":"NCT02164071","title":"Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies","phase":"","overall_status":"COMPLETED","enrollment_count":363,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT05554406","title":"Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":335,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02472145","title":"An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":326,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT06001385","title":"HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":313,"lead_sponsor_name":"Center for International Blood and Marrow Transplant Research","has_results":false},{"nct_id":"NCT04090736","title":"Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":302,"lead_sponsor_name":"PETHEMA Foundation","has_results":false},{"nct_id":"NCT03314974","title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT03287128","title":"Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin/Mylotarg®","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Versailles Hospital","has_results":false},{"nct_id":"NCT07108010","title":"ABO and Rh Blood Group Frequencies in Acute Leukemia Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT05218902","title":"A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)","phase":"","overall_status":"COMPLETED","enrollment_count":290,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT00801489","title":"Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":270,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04260022","title":"Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":242,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT03066648","title":"Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":241,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03404193","title":"Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":235,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03178617","title":"High-Intensity Parent Intervention Program in Improving Learning and School Functioning in Latino Children With Acute Leukemia or Lymphoblastic Lymphoma","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":214,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT02775903","title":"An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":213,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT02891551","title":"An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands","phase":"","overall_status":"COMPLETED","enrollment_count":209,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT01572662","title":"Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":201,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT06472128","title":"Novel Digital Application for Patients With Acute Leukemia","phase":"NA","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT02044796","title":"Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":199,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT05453903","title":"A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":196,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT05554419","title":"Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":184,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00804856","title":"Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT01627041","title":"Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":178,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00536601","title":"High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT03926624","title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":167,"lead_sponsor_name":"Delta-Fly Pharma, Inc.","has_results":false},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}